{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:42:27Z","timestamp":1770741747431,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.anndiagpath.2021.151725","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:31:18Z","timestamp":1613561478000},"page":"151725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer"],"prefix":"10.1016","volume":"52","author":[{"given":"Rebecca C.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Tarima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruizhe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Watchareepohn","family":"Palagnmonthip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Iczkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2021.151725_bb0005","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemotherapy Rep"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","journal-title":"J Urol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","article-title":"Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups","volume":"77","author":"van Leenders","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1309\/AJCPZ7WBU9YXSJPE","article-title":"Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome","volume":"136","author":"Iczkowski","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/modpathol.2014.116","article-title":"Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer","volume":"28","author":"Kweldam","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PAP.0000000000000168","article-title":"The new realization about cribriform prostate cancer","volume":"25","author":"Iczkowski","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0035","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2016.01.120","article-title":"Prognostic value of percent Gleason Grade 4 at prostate biopsy in predicting prostatectomy pathology and recurrence","volume":"196","author":"Cole","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.anndiagpath.2015.10.013","article-title":"Outcomes of Gleason score 3+ 4= 7 prostate cancer with minimal amounts (< 6%) vs\u2265 6% of Gleason pattern 4 tissue in needle biopsy specimens","volume":"20","author":"K\u0131r","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0050","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/cncr.23004","article-title":"Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy","volume":"110","author":"Cheng","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.juro.2018.07.062","article-title":"Clinical usefulness of total length of Gleason pattern 4 on biopsy in men with Grade Group 2 prostate cancer","volume":"201","author":"Dean","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0060","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/modpathol.2017.29","article-title":"Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer","volume":"30","author":"Kweldam","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151725_bb0065","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0090-4295(00)00753-6","article-title":"Prognostic significance of Gleason score 3+ 4 versus Gleason score 4+ 3 tumor at radical prostatectomy","volume":"56","author":"Chan","year":"2000","journal-title":"Urology"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421000253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421000253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:32:06Z","timestamp":1761078726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913421000253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":13,"alternative-id":["S1092913421000253"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151725","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151725"}}